|
|
|
|
|
|
by pessimizer
779 days ago
|
|
|
That's just your bias. > Several inhaler manufacturers formed the International Pharmaceutical Aerosol Consortium, a lobbying group dedicated to, among other goals, persuading lawmakers and regulators to ban inhalers with CFCs. The group spent hundreds of
thousands of dollars, and in 2005, the FDA ruled that CFC inhalers would be phased out beginning in 2009. As a result of the ban, newer albuterol products — including Proventil HFA (which was approved in 1996), Ventolin HFA (approved in 2001), and ProAir HFA (approved in 2004) — would be free from competition from inexpensive CFC-containing generics. HFA inhalers were protected by new patents on both the HFA propellants and the devices themselves, and they generally cost much more than generic CFC inhalers. "Product Hopping in the Drug Industry - Lessons from Albuterol" N Engl J Med. 2022 Sep 29;387(13):1153-1156. doi: 10.1056/NEJMp2208613. Epub 2022 Sep 24. https://pubmed.ncbi.nlm.nih.gov/36155425/ [pdf] https://wvpublic.org/wp-content/uploads/2023/06/Tu-2022-Wout... |
|
|